Multiple Sclerosis (MS) – ncbi.nlm.nih.gov

Evidence reviews Treatment of seizures for patients with multiple sclerosis

Epileptic seizures occur in a relatively small number of patients with multiple sclerosis, but can have serious consequences. Because the cause of epileptic seizures in patients in MS may be different from that in other forms of epilepsy, it is uncertain whether patients with MS should be treated differently. We searched for studies on the treatment of epileptic seizures in patients with MS, but found none. Well designed studies that address this issue are needed.

Multiple sclerosis (MS) is an immune disease of the nervous system. Drugs that interfere with the immune system, such as methotrexate could benefit people with the disease. To date research suggest that there may be small improvements from treatment with methotrexate. However, until these improvements need to be balanced against methotrexate's potentially serious sideeffects. Until larger research studies are performed, it will be too early to say whether the benefits of this drug outweigh its sideeffects.

Multiple sclerosis (MS) is a chronic disease of the nervous system which affects young and middleaged adults. Spasticity, a common problem in people with MS, is a disorder of voluntary movement caused by damage to the central nervous system. The main sign is the resistance to passive movement of a limb but other associated features pain, spasms, loss of function affect people's quality of life more directly.

See all (368)

In 2015, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of fingolimod compared with the standard therapies for people with rapidly evolving severe RRMS. For these people, fingolimod is an alternative to standard therapies that use interferon beta or glatiramer acetate.IQWiG assessed the data from a study involving a total of 121 patients. Half of the participants were treated with fingolimod, while the rest used interferon beta.

In 2016, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of fingolimod compared with the standard therapies for people with highly active relapsing remitting multiple sclerosis (RRMS).The following results apply to patients who still had active multiple sclerosis despite using glatiramer acetate therapy at a sufficient.For this group of patients, data from one study was available: 17 of the participants took fingolimod and 25 had the standard therapy with interferon beta as follow-up treatment.

Epileptic seizures occur in a relatively small number of patients with multiple sclerosis, but can have serious consequences. Because the cause of epileptic seizures in patients in MS may be different from that in other forms of epilepsy, it is uncertain whether patients with MS should be treated differently. We searched for studies on the treatment of epileptic seizures in patients with MS, but found none. Well designed studies that address this issue are needed.

See all (80)

See the article here:
Multiple Sclerosis (MS) - ncbi.nlm.nih.gov